Sasanlimab represents a highly specialized humanized IgG4 monoclonal antibody specifically engineered to target the human programmed cell death protein 1 (PD-1) with exceptional binding affinity. It effectively facilitates the measurable blockade of the PD-1/PD-L1 and PD-1/PD-L2 inhibitory axes across various preclinical experimental models to evaluate the restoration of T-cell mediated anti-tumor immunity and the reversal of immune exhaustion during strictly monitored laboratory observation periods.